| Investor Relations |
Consolidated Statements of Cash Flows
Mitsubishi Pharma Corporation and Consolidated Subsidiaries
Years ended March 31, 2006 and 2005
Millions of yen Thousands of
U.S. dollars
(Note 3)
2006 2005 2006
Cash flows from operating activities
   Income before income taxes and minority interests 
¥ 34,471 ¥ 24,394 $ 294,624
   Adjustments to reconcile income before income taxes and
      minority interests to net cash provided by operating activities:
         Depreciation and amortization 
11,796 11,457 100,821
         Loss on impairment of fixed assets 
333 3,535 2,846
         Decrease in accrued retirement benefits 
(1,998 ) (6,620 ) (17,077 )
         Interest and dividend income 
(263 ) (186 ) (2,248 )
         Interest expense 
174 286 1,487
         Equity in losses of unconsolidated subsidiaries
            and affiliates 
81 315 692
         Gain on sales of investments in securities 
(605 ) (260 ) (5,171 )
         Gain on sales of property, plant and equipment 
(1,322 ) (1,595 ) (11,299 )
         Loss on disposal of property, plant and equipment 
189 302 1,615
         Gain on foreign exchange 
(366 ) (49 ) (3,128 )
         Changes in operating assets and liabilities:
            Notes and accounts receivable, trade 
7,870 4,111 67,265
            Inventories 
1,639 1,689 14,009
            Notes and accounts payable, trade 
1,059 1,411 9,051
            Consumption taxes payable 
101 (116 ) 863
         Other, net 
(5,607 ) 656 (47,923 )
            Subtotal 
47,552 39,330 406,427
         Interest and dividends received 
258 186 2,205
         Interest paid 
(181 ) (292 ) (1,547 )
         Income taxes paid 
(10,600 ) (11,791 ) (90,598 )
            Net cash provided by operating activities 
37,029 27,433 316,487
 
Cash flows from investing activities
  Increase in time deposits
(1,000 )    (8,547 )
  Decrease in time deposits
   5   
  Purchases of property, plant and equipment 
(11,804 ) (10,483 ) (100,889 )
  Proceeds from sales of property, plant and equipment 
2,691 4,264 23,000
  Proceeds from sales of investments in securities 
1,427 829 12,197
  Purchases of investments in securities 
(969 ) (26 ) (8,282 )
  Other, net 
(217 ) (1,539 ) (1,855 )
            Net cash used in investing activities 
(9,872 ) (6,950 ) (84,376 )
 
Cash flows from financing activities
  Decrease in short-term loans, net 
(979 ) (260 ) (8,367 )
  Repayment of long-term debt 
(1,396 ) (5,347 ) (11,932 )
  Cash dividends paid 
(4,525 ) (4,533 ) (38,675 )
  Cash dividends paid to minority interests 
(634 ) (43 ) (5,419 )
  Other, net 
(278 ) (403 ) (2,376 )
            Net cash used in financing activities 
(7,812 ) (10,586 ) (66,769 )
 
Effect of exchange rate changes on cash and cash equivalents 
307 99 2,624
Increase in cash and cash equivalents 
19,652 9,996 167,966
Cash and cash equivalents at beginning of year 
44,192 34,196 377,710
Increase in cash and cash equivalents resulting
  from inclusion of a consolidated subsidiary 
13    111
Decrease in cash and cash equivalents resulting
  from exclusion of consolidated subsidiaries 
(45 )    (385 )
Cash and cash equivalents at end of year (Note 16
¥ 63,812 ¥ 44,192 $ 545,402
See accompanying notes to consolidated financial statements.
  
AR TOP |

Profile
Financial Highlights
Message from the President
Business results
Establishment of Joint Holding Company
Launch of Joint Holding Company, Mitsubishi Chemical Holdings Corporation, from October 2005
Strengthening Pharmaceutical Business through Joint Holding Company Structure
Meeting Tomorrow’s Challenge in Personalized Medicine
Mid-term Corporate Action Plan
Mid-term Corporate Action Plan — On Target
Maximization of Sales and Marketing Strengths
Optimization of Production and Technology Divisions
Target of Total Cost Reduction Achieved
Increasing the Certainty of Research and Development Results and Establishment of Global Marketing Basis
R&D
Strengthening Research and Development
Product Pipeline
Corporate Social Responsibility
Improving Corporate Governance System
Reinforced Implementation of Compliance
Global Environmental Conservation: a Task for Every Individual
Harmony with Society
Financial Section
Five-Year Summary
Management’s Discussion and Analysis
Balance Sheets
Income Statements
Shareholders’ Equity
Cash Flows
Notes
Auditors’ Report
Corporate Data

Mitsubishi Chemical Holdings Corporation Investor Center
Copyright© Mitsubishi Pharma Corporation. All Rights Reserved.